ATA1302001A - Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen - Google Patents

Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen

Info

Publication number
ATA1302001A
ATA1302001A AT0013001A AT1302001A ATA1302001A AT A1302001 A ATA1302001 A AT A1302001A AT 0013001 A AT0013001 A AT 0013001A AT 1302001 A AT1302001 A AT 1302001A AT A1302001 A ATA1302001 A AT A1302001A
Authority
AT
Austria
Prior art keywords
specific pathogen
isolating
identifying
antigens against
producing antigens
Prior art date
Application number
AT0013001A
Other languages
English (en)
Other versions
AT410798B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to AT0013001A priority Critical patent/AT410798B/de
Priority to KR1020087026439A priority patent/KR20080107477A/ko
Priority to EP05108422A priority patent/EP1616876A3/de
Priority to PL392964A priority patent/PL214482B1/pl
Priority to RU2003125967/13A priority patent/RU2289817C2/ru
Priority to EP10178468A priority patent/EP2412722A1/de
Priority to PCT/EP2002/000546 priority patent/WO2002059148A2/en
Priority to CA2792244A priority patent/CA2792244A1/en
Priority to AT02716669T priority patent/ATE309268T1/de
Priority to US10/470,048 priority patent/US7968297B2/en
Priority to AU2002247641A priority patent/AU2002247641B8/en
Priority to KR1020037009882A priority patent/KR100851728B1/ko
Priority to EP10178476A priority patent/EP2319861A1/de
Priority to CA2436057A priority patent/CA2436057C/en
Priority to NZ527440A priority patent/NZ527440A/xx
Priority to KR1020097017433A priority patent/KR20090101973A/ko
Priority to EP05024214.8A priority patent/EP1630172B1/de
Priority to IL15708202A priority patent/IL157082A0/xx
Priority to DK02716669T priority patent/DK1355930T3/da
Priority to EP10178465A priority patent/EP2322539A3/de
Priority to HU0402048A priority patent/HUP0402048A3/hu
Priority to CNA2008101610502A priority patent/CN101492496A/zh
Priority to SK1049-2003A priority patent/SK10492003A3/sk
Priority to KR1020087006114A priority patent/KR100901915B1/ko
Priority to JP2002559450A priority patent/JP2004531476A/ja
Priority to EP02716669A priority patent/EP1355930B1/de
Priority to CNA028057651A priority patent/CN1649894A/zh
Priority to MXPA03006702A priority patent/MXPA03006702A/es
Priority to NZ540764A priority patent/NZ540764A/en
Priority to NZ565349A priority patent/NZ565349A/en
Priority to BR0207067-7A priority patent/BR0207067A/pt
Priority to DE60207194T priority patent/DE60207194T2/de
Priority to CZ20032201A priority patent/CZ20032201A3/cs
Priority to ES02716669T priority patent/ES2252438T3/es
Priority to NZ551802A priority patent/NZ551802A/xx
Priority to PL367125A priority patent/PL209115B1/pl
Publication of ATA1302001A publication Critical patent/ATA1302001A/de
Application granted granted Critical
Priority to NO20033364A priority patent/NO20033364L/no
Priority to IS6895A priority patent/IS6895A/is
Priority to ZA200305764A priority patent/ZA200305764B/en
Publication of AT410798B publication Critical patent/AT410798B/de
Priority to AU2006249236A priority patent/AU2006249236B2/en
Priority to US11/614,716 priority patent/US7771728B2/en
Priority to IL186706A priority patent/IL186706A/en
Priority to AU2007234519A priority patent/AU2007234519B2/en
Priority to JP2008152742A priority patent/JP5053933B2/ja
Priority to AU2010200549A priority patent/AU2010200549A1/en
Priority to US12/853,074 priority patent/US8323660B2/en
Priority to IL211037A priority patent/IL211037A/en
Priority to IL211038A priority patent/IL211038A0/en
Priority to US13/613,761 priority patent/US8715688B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT0013001A 2001-01-21 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen AT410798B (de)

Priority Applications (49)

Application Number Priority Date Filing Date Title
AT0013001A AT410798B (de) 2001-01-26 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
KR1020087026439A KR20080107477A (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는 방법
EP05108422A EP1616876A3 (de) 2001-01-26 2002-01-21 Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
PL392964A PL214482B1 (pl) 2001-01-26 2002-01-21 Antygen reaktywny wobec surowicy hiperimmunologicznej, zastosowanie tego antygenu, preparat farmaceutyczny zawierajacy antygen, szczepionka, przeciwcialo, preparat zawierajacy przeciwcialo, sposób wytwarzania preparatu i czasteczka kwasu nukleinowego
RU2003125967/13A RU2289817C2 (ru) 2001-01-26 2002-01-21 Способ идентификации, выделения и получения антигенов определенного патогена
EP10178468A EP2412722A1 (de) 2001-01-26 2002-01-21 Verfahren zur Identifikation, Isolierung und Herstellung von Antigenen gegen spezifische Pathogene
PCT/EP2002/000546 WO2002059148A2 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
CA2792244A CA2792244A1 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
AT02716669T ATE309268T1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
US10/470,048 US7968297B2 (en) 2001-01-26 2002-01-21 Method for identification, isolation and production of antigens to a specific pathogen
AU2002247641A AU2002247641B8 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
KR1020037009882A KR100851728B1 (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는 방법
EP10178476A EP2319861A1 (de) 2001-01-26 2002-01-21 Verfahren zur Identifikation, Isolierung und Herstellung von Antigenen gegen spezifische Pathogene
CA2436057A CA2436057C (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
NZ527440A NZ527440A (en) 2001-01-26 2002-01-21 A method for indentification, isolation and production of antigens to a specific pathogen
KR1020097017433A KR20090101973A (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는 방법
EP05024214.8A EP1630172B1 (de) 2001-01-26 2002-01-21 Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
IL15708202A IL157082A0 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
DK02716669T DK1355930T3 (da) 2001-01-26 2002-01-21 Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
EP10178465A EP2322539A3 (de) 2001-01-26 2002-01-21 Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
HU0402048A HUP0402048A3 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
CNA2008101610502A CN101492496A (zh) 2001-01-26 2002-01-21 鉴定,分离及生产特异性病原体抗原的方法
SK1049-2003A SK10492003A3 (sk) 2001-01-26 2002-01-21 Spôsob identifikácie, izolácie a produkcie antigénov špecifického patogénu
KR1020087006114A KR100901915B1 (ko) 2001-01-26 2002-01-21 특이적 병원균에 대한 항원을 동정하고 분리하여 생산하는방법
JP2002559450A JP2004531476A (ja) 2001-01-26 2002-01-21 特定の病原体に対する抗原の同定、単離および製造方法
EP02716669A EP1355930B1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
CNA028057651A CN1649894A (zh) 2001-01-26 2002-01-21 鉴定,分离及生产特异性病原体抗原的方法
MXPA03006702A MXPA03006702A (es) 2001-01-26 2002-01-21 Metodo para la identificacion, aislamiento y produccion de antigenos para un patogeno especifico.
NZ540764A NZ540764A (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
NZ565349A NZ565349A (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
BR0207067-7A BR0207067A (pt) 2001-01-26 2002-01-21 Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
DE60207194T DE60207194T2 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CZ20032201A CZ20032201A3 (en) 2001-01-26 2002-01-21 A method for identification, isolation and production of antigens to a specific pathogen
ES02716669T ES2252438T3 (es) 2001-01-26 2002-01-21 Procedimiento para la identificacion, aislamiento y produccion de antigenos para un patogeno especifico.
NZ551802A NZ551802A (en) 2001-01-26 2002-01-21 A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof
PL367125A PL209115B1 (pl) 2001-01-26 2002-01-21 Sposób identyfikowania, izolowania i wytwarzania antygenów od specyficznego patogenu
NO20033364A NO20033364L (no) 2001-01-26 2003-07-25 Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen
IS6895A IS6895A (is) 2001-01-26 2003-07-25 Aðferð til að bera kennsl á, einangra og vinna mótefnavaka við ákveðnum sjúkdómsvaldi
ZA200305764A ZA200305764B (en) 2001-01-26 2003-07-25 A method for identification, isolation and production of antigens to a specific pathogen.
AU2006249236A AU2006249236B2 (en) 2001-01-26 2006-12-04 A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen
US11/614,716 US7771728B2 (en) 2001-01-21 2006-12-21 Method for identification, isolation and production of antigens to a specific pathogen
IL186706A IL186706A (en) 2001-01-26 2007-10-17 Method for identification, isolation and production of antigens to a specific pathogen
AU2007234519A AU2007234519B2 (en) 2001-01-26 2007-11-16 A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen
JP2008152742A JP5053933B2 (ja) 2001-01-26 2008-06-11 特定の病原体に対する抗原の同定、単離および製造方法
AU2010200549A AU2010200549A1 (en) 2001-01-26 2010-02-12 A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen
US12/853,074 US8323660B2 (en) 2001-01-26 2010-08-09 Method for identification, isolation and production of antigens to a specific pathogen
IL211037A IL211037A (en) 2001-01-26 2011-02-03 Antigen @ reactant @ with @ serum @ hyper
IL211038A IL211038A0 (en) 2001-01-26 2011-02-03 A method for identification, isolation and production of antigens to a specific pathogen
US13/613,761 US8715688B2 (en) 2001-01-26 2012-09-13 Method for identification, isolation and production of antigens to a specific pathogen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0013001A AT410798B (de) 2001-01-26 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen

Publications (2)

Publication Number Publication Date
ATA1302001A true ATA1302001A (de) 2002-12-15
AT410798B AT410798B (de) 2003-07-25

Family

ID=3636418

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0013001A AT410798B (de) 2001-01-21 2001-01-26 Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AT02716669T ATE309268T1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02716669T ATE309268T1 (de) 2001-01-26 2002-01-21 Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens

Country Status (24)

Country Link
US (4) US7968297B2 (de)
EP (6) EP2319861A1 (de)
JP (2) JP2004531476A (de)
KR (4) KR100851728B1 (de)
CN (2) CN1649894A (de)
AT (2) AT410798B (de)
AU (3) AU2002247641B8 (de)
BR (1) BR0207067A (de)
CA (2) CA2792244A1 (de)
CZ (1) CZ20032201A3 (de)
DE (1) DE60207194T2 (de)
DK (1) DK1355930T3 (de)
ES (1) ES2252438T3 (de)
HU (1) HUP0402048A3 (de)
IL (4) IL157082A0 (de)
IS (1) IS6895A (de)
MX (1) MXPA03006702A (de)
NO (1) NO20033364L (de)
NZ (4) NZ551802A (de)
PL (2) PL209115B1 (de)
RU (1) RU2289817C2 (de)
SK (1) SK10492003A3 (de)
WO (1) WO2002059148A2 (de)
ZA (1) ZA200305764B (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708949C (en) 2001-01-03 2016-03-08 Epitopix Llc. Immunizing compositions and methods of use
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
GB0200865D0 (en) * 2002-01-16 2002-03-06 Univ Bristol Method
GB2387600A (en) * 2002-04-19 2003-10-22 Pantherix Ltd Pantothenate kinase
AU2003249851A1 (en) * 2002-10-03 2004-04-23 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
EP1601770B1 (de) 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigene
CA2520868A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
EP1615950A2 (de) 2003-04-15 2006-01-18 Intercell AG Antigene gegen s. pneumoniae
JP2007524366A (ja) * 2003-04-22 2007-08-30 インターツェル・アクチェンゲゼルシャフト ピロリ菌抗原
EP2275435A3 (de) * 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigene I + II
CA2525540A1 (en) * 2003-05-30 2004-12-09 Intercell Ag Enterococcus antigens
RU2257217C2 (ru) * 2003-07-08 2005-07-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Гипериммунный тканевой препарат
HRP20100240T1 (hr) * 2003-07-24 2010-09-30 Merck Sharp & Dohme Corp. Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus
WO2005009378A2 (en) * 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
AU2004274977B2 (en) 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
JP2007528217A (ja) * 2004-02-18 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
WO2005086663A2 (en) * 2004-02-27 2005-09-22 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphlococcus aureus
JP2005278537A (ja) * 2004-03-30 2005-10-13 Dai Ichi Seiyaku Co Ltd 新規ポリペプチド
EP1740604A2 (de) * 2004-04-27 2007-01-10 Intercell AG Td-antigene
US7842479B2 (en) 2004-05-21 2010-11-30 The Board Of Regents Of The University Of Nebraska Methods for altering acetic acid production and enhancing cell death in bacteria
CN1956727A (zh) * 2004-05-25 2007-05-02 默克公司 诱导抗金黄色葡萄球菌的保护性免疫应答的多肽
WO2005120563A2 (en) * 2004-06-04 2005-12-22 Pharmexa Inc. Induction of an immune response against streptococcus pneumoniae polysaccharides
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
EP1784212A4 (de) * 2004-07-06 2008-09-17 Merck & Co Inc Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
US20080095792A1 (en) * 2004-09-17 2008-04-24 Anderson Annaliesa S Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
AU2005287505A1 (en) 2004-09-22 2006-03-30 Biosynexus Incorporated Staphylococcal immunogenic compositions
CA2583121A1 (en) 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
ES2327432T3 (es) * 2004-10-29 2009-10-29 Intercell Ag Vacunas contra el vhc para pacientes con vhc cronica.
US7718182B2 (en) 2005-01-21 2010-05-18 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
DK1848732T3 (en) 2005-01-21 2016-11-14 Epitopix Llc YERSINIA SPP.-POLYPEPTIDES AND METHODS OF USE
CA2597263C (en) 2005-02-14 2017-01-17 Epitopix, Llc Polypeptides from staphylococcus aureus and methods of use
JP2008534970A (ja) * 2005-04-04 2008-08-28 ヴィヴェンティア バイオテック インコーポレーティッド 抗原の同定のための方法および系
WO2006121664A2 (en) * 2005-05-05 2006-11-16 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
US20090220538A1 (en) * 2005-07-14 2009-09-03 Bharat Biotech International Limited vaccine for staphylococcal infections
EP2368570A3 (de) * 2006-01-18 2012-05-02 University Of Chicago Zusammensetzungen und Verfahren in Verbindung mit Stayphylokokken-Bakterienproteinen
EA015833B1 (ru) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
WO2008031133A2 (en) * 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
US20080102067A1 (en) * 2006-10-25 2008-05-01 Cook Mark E Immunogenic composition
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP1935984A1 (de) * 2006-12-20 2008-06-25 Unilever N.V. Screening-Verfahren zur Identifizierung eines Konservierungsmittels
US8124108B2 (en) 2007-01-24 2012-02-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus epidermidis
EP2126070A4 (de) * 2007-03-19 2010-03-31 Merck Sharp & Dohme Polypeptide zur induzierung einer schützenden immunantwort gegen staphylococcus epidermidis
US20100203075A1 (en) * 2007-06-18 2010-08-12 Intercell Ag Chlamydia antigens
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CN101951948B (zh) 2007-08-31 2015-12-09 芝加哥大学 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物
CA2702696A1 (en) * 2007-10-18 2009-04-23 Unilever Plc Method for producing a foaming agent
CN101458255B (zh) * 2007-12-14 2013-03-06 武汉大学 丙型肝炎病毒包膜抗原夹心法试剂盒及检测方法
US20090196852A1 (en) * 2008-02-04 2009-08-06 Watkinson D Tobin Compositions and methods for diagnosing and treating immune disorders
DK2268618T3 (en) 2008-03-03 2015-08-17 Novartis Ag Compounds and compositions as TLR aktivitetsmodulatorer
CA2718473A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
WO2009158682A2 (en) * 2008-06-27 2009-12-30 Watkinson D Tobin Compositions and methods for diagnosing and treating pathogenic disorders
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP2344189B1 (de) * 2008-09-30 2018-05-30 University of Maryland, Baltimore Impfstoff zum schutz gegen staphylococcus aureus-biofilme mit zellwandassoziierten immunogenen
WO2010042481A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
DK2346987T3 (en) * 2008-10-16 2016-04-25 Unilever Nv Hydrophobin solution with anti-foaming agent
EP2376111A4 (de) 2008-11-26 2013-01-09 Merck Sharp & Dohme Polypeptide zur induzierung einer schützenden immunantwort gegen staphylococcus aureus
EP2384201A4 (de) 2008-11-26 2013-01-09 Merck Sharp & Dohme Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
RU2371201C1 (ru) * 2008-12-15 2009-10-27 Гурий Петрович Ступаков Способ лечения хронических заболеваний
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
US9932373B2 (en) * 2009-03-23 2018-04-03 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
CA3154626A1 (en) * 2009-04-14 2010-10-21 Glaxosmithkline Biologicals S.A. Compositions for immunising against staphylococcus aureus
CA2704702C (en) * 2009-06-02 2018-06-12 Unilever Plc Aerated baked products
EP2440245B1 (de) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphtyridin-enthaltende impfstoffe
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
EP2549990A1 (de) 2010-03-23 2013-01-30 Irm Llc Verbindungen (cysteinbasierte lipopeptide) und zusammensetzungen als tlr2-agonisten zur behandlung von infektionen, entzündungen, atemwegserkrankungen etc.
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
BR112012029521A2 (pt) * 2010-05-05 2018-03-06 New York University leucocidinas do staphylococcus aureus, composições terapêuticas, e aplicações das mesmas.
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2593133A4 (de) 2010-07-13 2014-11-26 Merck Sharp & Dohme Staphylococcus aureus-oberflächenprotein sa1789 und darauf basierender schutzimpfstoff
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
EP2638058B1 (de) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase-peptid-konjugat-impfstoffe gegen staphylococcus aureus
CN102558316B (zh) * 2010-12-30 2015-07-01 上海雅心生物技术有限公司 高稳定性的具抗体结合能力的重组蛋白a及其生产
US8945588B2 (en) * 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2012177658A2 (en) * 2011-06-19 2012-12-27 New York Univeristy Methods of treating and preventing staphylococcus aureus infections and associated conditions
ES2609817T3 (es) 2011-06-19 2017-04-24 New York University Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
EP2773370A4 (de) 2011-10-31 2016-09-28 Merck Sharp & Dohme Schutzimpfstoff auf grundlage des staphylococcus aureus-proteins sa2451
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
WO2013162746A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
US9376487B2 (en) 2012-07-10 2016-06-28 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2493 protein
RU2526497C2 (ru) * 2012-10-31 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохарнения и социального развития Российской Федерации Способ определения генотипов золотистого стафилококка
DK2917360T3 (da) * 2012-11-06 2020-03-30 Medimmune Llc Antistoffer mod S. aureus-overflade-determinanter
US9873733B2 (en) * 2012-12-20 2018-01-23 Morphosys Ag. Anti-staphylococcal antibodies
CN103965336B (zh) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
KR101808223B1 (ko) * 2013-04-25 2017-12-13 주식회사 앱틀라스 자가 절단 카세트를 포함하는 단백질 정제 방법 및 이의 용도
LT3038633T (lt) * 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN104558196A (zh) * 2013-10-15 2015-04-29 温州医科大学 基于HBcAg载体的沙眼衣原体主要外膜蛋白表位疫苗及其用途
RU2542396C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ и набор для ускоренной лабораторной диагностики коклюшной инфекции
US20160368952A1 (en) * 2013-12-03 2016-12-22 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
CN103694323B (zh) * 2013-12-09 2017-01-18 成都欧林生物科技股份有限公司 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
KR102481455B1 (ko) * 2014-06-30 2022-12-26 머독 칠드런스 리서치 인스티튜트 헬리코박터 치료제
CN104569386B (zh) * 2014-12-10 2016-05-11 中国水产科学研究院淡水渔业研究中心 一种罗非鱼源无乳链球菌elisa快速检测试剂盒及其检测方法
RU2711364C2 (ru) * 2014-12-17 2020-01-16 Ф. Хоффманн-Ля Рош Аг Ферментативная однореакторная реакция двойного конъюгирования полипептидов за одну стадию с использованием сортазы
WO2016197071A1 (en) 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
WO2017050872A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
JP6895953B2 (ja) 2015-09-25 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼａを利用してチオエステルを作製するための方法
JP6998862B2 (ja) 2015-09-25 2022-02-04 エフ．ホフマン－ラ ロシュ アーゲー 可溶性ソルターゼａ
LT3380508T (lt) 2015-11-27 2020-11-10 Masarykova Univerzita Termostabilus fgf2 polipeptidas, jo panaudojimas
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10504742B2 (en) * 2017-05-31 2019-12-10 Asm Ip Holding B.V. Method of atomic layer etching using hydrogen plasma
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
EP3752182B1 (de) 2018-02-12 2024-05-15 Inimmune Corporation Toll-like-rezeptorliganden
US10905738B2 (en) 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
RU2689161C1 (ru) * 2018-10-04 2019-05-24 Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения бактериальных антигенов
CN111110838A (zh) * 2019-12-24 2020-05-08 华南师范大学 一种罗非鱼无乳链球菌疫苗及其制备方法
US20230204567A1 (en) * 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
CN111808977B (zh) * 2020-07-23 2023-06-27 清华大学深圳国际研究生院 一种由snp所引起利福平类抗生素耐药的抗性基因的特异性引物的设计方法及检测方法
KR20230117105A (ko) 2020-11-04 2023-08-07 엘리고 바이오사이언스 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도
KR102306010B1 (ko) * 2021-04-07 2021-09-27 씨제이제일제당 (주) 신규한 분지쇄아미노산 투과효소 변이체 및 이를 이용한 l-발린 생산 방법
KR102281369B1 (ko) * 2021-04-07 2021-07-22 씨제이제일제당 (주) 신규한 디히드로리포일 아세틸기전이효소 변이체 및 이를 이용한 l-발린 생산 방법
CN120028542B (zh) * 2025-01-17 2025-11-25 宁夏医科大学 血清抗体IgG特异识别其疫苗株抗原谱及其筛选方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606921B1 (de) * 1989-03-09 2000-08-02 American Cyanamid Company Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
US5980908A (en) 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
US5456907A (en) 1992-01-10 1995-10-10 Helene Curtis, Inc. Cysteamine permanent wave composition and method
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
CA2310381A1 (en) * 1997-12-05 1999-06-17 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Method and cells to screen combinatorial libraries
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE1073771T1 (de) * 1998-04-30 2002-06-13 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Neue methode zur selektion von klonen einer expressionsbibliothek mittels "rearraying"
EP1090111A1 (de) * 1998-06-25 2001-04-11 Institut Pasteur Erschöpfende analyse von viralen protein wechselwirkungen mittels des "two-hybrid" verfahrens und selektion von korrekt gefalteten viralen interagierenden polypeptiden
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
AT407643B (de) * 1999-02-01 2001-05-25 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DK2230303T3 (da) 1999-05-05 2013-04-15 Phylogica Ltd Isolering af biologiske modulatorer fra biodiverse genfragment-biblioteker
DE1238102T1 (de) * 1999-08-06 2003-05-28 Ivigene Corp., Alachua Mikrobielle polynukleotide, die während der infekton eines wirts exprimiert werden
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20020061569A1 (en) 2000-03-21 2002-05-23 Robert Haselbeck Identification of essential genes in prokaryotes
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002102829A2 (en) 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
JP4404627B2 (ja) 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
HRP20100240T1 (hr) 2003-07-24 2010-09-30 Merck Sharp & Dohme Corp. Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus
EP1976066B1 (de) 2005-06-13 2015-08-12 BlackBerry Limited Elektrischer Steckverbinder und System für ein Bauteil in einem elektronischen Gerät

Also Published As

Publication number Publication date
AU2002247641B2 (en) 2007-08-23
JP2008291035A (ja) 2008-12-04
NZ527440A (en) 2006-02-24
BR0207067A (pt) 2004-06-15
DE60207194T2 (de) 2006-08-03
US8715688B2 (en) 2014-05-06
CZ20032201A3 (en) 2004-03-17
US20130034575A1 (en) 2013-02-07
WO2002059148A8 (en) 2003-01-16
DE60207194D1 (de) 2005-12-15
NZ565349A (en) 2009-07-31
KR20090101973A (ko) 2009-09-29
RU2003125967A (ru) 2005-03-10
AU2010200549A1 (en) 2010-03-04
IL157082A0 (en) 2004-02-08
EP1616876A2 (de) 2006-01-18
AU2007234519A1 (en) 2007-12-13
WO2002059148A9 (en) 2002-10-31
WO2002059148A3 (en) 2003-07-31
EP1355930A2 (de) 2003-10-29
CN101492496A (zh) 2009-07-29
PL367125A1 (en) 2005-02-21
US20110020402A1 (en) 2011-01-27
RU2289817C2 (ru) 2006-12-20
EP1616876A3 (de) 2006-04-12
US7968297B2 (en) 2011-06-28
MXPA03006702A (es) 2005-04-08
CA2436057C (en) 2012-12-18
WO2002059148A2 (en) 2002-08-01
SK10492003A3 (sk) 2004-07-07
PL209115B1 (pl) 2011-07-29
IL186706A0 (en) 2008-02-09
NZ540764A (en) 2008-03-28
NO20033364L (no) 2003-09-24
US20080038287A1 (en) 2008-02-14
US7771728B2 (en) 2010-08-10
CA2792244A1 (en) 2002-08-01
EP2322539A2 (de) 2011-05-18
IL211037A0 (en) 2011-04-28
ES2252438T3 (es) 2006-05-16
AU2002247641B8 (en) 2008-03-13
US20050037444A1 (en) 2005-02-17
KR20080107477A (ko) 2008-12-10
EP2319861A1 (de) 2011-05-11
EP2412722A1 (de) 2012-02-01
IS6895A (is) 2003-07-25
EP1630172B1 (de) 2015-06-10
KR20030082574A (ko) 2003-10-22
ZA200305764B (en) 2004-07-26
JP2004531476A (ja) 2004-10-14
PL214482B1 (pl) 2013-08-30
US8323660B2 (en) 2012-12-04
EP2322539A3 (de) 2011-09-07
NO20033364D0 (no) 2003-07-25
EP1630172A3 (de) 2006-05-03
KR20080029016A (ko) 2008-04-02
NZ551802A (en) 2008-04-30
AT410798B (de) 2003-07-25
HUP0402048A2 (hu) 2005-01-28
KR100901915B1 (ko) 2009-06-10
ATE309268T1 (de) 2005-11-15
CA2436057A1 (en) 2002-08-01
AU2007234519B2 (en) 2009-11-12
EP1630172A2 (de) 2006-03-01
DK1355930T3 (da) 2006-03-06
KR100851728B1 (ko) 2008-08-11
JP5053933B2 (ja) 2012-10-24
IL211037A (en) 2013-07-31
EP1355930B1 (de) 2005-11-09
IL186706A (en) 2010-12-30
CN1649894A (zh) 2005-08-03
HUP0402048A3 (en) 2010-01-28
PL392964A1 (pl) 2011-01-03
IL211038A0 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
ATA1302001A (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
DE60126156D1 (de) Verfahren und vorrichtung zur herstellung von knochenzement
DE60206472D1 (de) Verfahren und vorrichtung zur herstellung von mineralwolle
DE50006246D1 (de) Verfahren und vorrichtung zur herstellung von borstenwaren und danach hergestellte borstenwaren
DE60301350D1 (de) Verfahren zur herstellung von 7-substituierten -3-chinolin und 3-chinol-4-on carbonitrile
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
DE60328150D1 (de) System und Methode zur Erzeugung von Anfangs-Vektoren
DE60232605D1 (de) Verfahren zur herstellung von durchblasgetrocknetem tissueprodukt mit abdampfrückgewinnung
AT4947U3 (de) Vollnarbiges rindnappaleder und verfahren zur herstellung desselben
DE60334747D1 (de) Verfahren und Vorrichtung zur Herstellung von Microarrays
DE50304943D1 (de) Verfahren und vorrichtung zur herstellung von borsten
DE60232600D1 (de) Verfahren und vorrichtung zur herstellung von percarbonsäure
EP1487480A4 (de) Fusionsmoleküle und verfahren zur behandlung von immunkrankheiten
ATE246512T1 (de) Verfahren zur herstellung von inaktivierten, w/ö emulsion adjuvierten, impfstoffen
DE50306404D1 (de) Verfahren und vorrichtung zur herstellung von vorgarnlunte
ATE531724T1 (de) Verfahren zur herstellung von peptiden
ATE509892T1 (de) Verfahren zur herstellung von magnetitteilchen
DE60316020D1 (de) Verfahren und vorrichtung zur herstellung und rückführung von fluor
DE50208126D1 (de) Verfahren zur Herstellung von Aminoalkylsilanen und Alkylaminen
EP1578461A4 (de) Impfstoffe gegen hiv-tat-protein zur erzeugung von neutralisierenden antikörpern
ATA12999A (de) Verfahren zur selektion und herstellung von vakzin- und diagnostika-präparationen
ATE406806T1 (de) Verfahren zur herstellung von sojazuckern und davon abgeleitetes produkt
WO2007030771A3 (en) Targeted identification of immunogenic peptides
DE60229365D1 (de) Verfahren zur Aktivierung von Antigenen
DE50213291D1 (de) Verfahren und vorrichtung zur herstellung von nebenformelementen

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee